@stapleyourmouthshut's testosterone claims, fact-checked

What did @stapleyourmouthshut actually say?

A creator marking their one-year anniversary on testosterone ran through the changes they experienced, framed as a personal share rather than medical advice. They covered clitoral growth ("bottom growth"), increased sex drive, fat redistribution, jaw shifts causing dental changes, emotional processing changes, increased hunger, voice soreness during drops, and the need for blood draws every three to six months. They closed with a genuine push: "your well-being and safety is first." This is the kind of anecdotal rundown that racks up views precisely because it feels honest and unscripted. Most of it is, frankly, pretty reasonable. A few things could use more precision.

Does the science back this up?

Mostly yes, with important caveats. The core physical effects they describe are well-documented in the literature on gender-affirming testosterone therapy. Fat redistribution, clitoral growth, voice changes, and libido increases are consistent findings across multiple cohort studies. The blood monitoring recommendation is accurate and actually undersells the clinical picture a bit.

A 2021 review by Weinand and Safer in Journal of Clinical Endocrinology and Metabolism confirmed that testosterone in transmasculine patients produces significant body composition changes, including visceral fat increase and lean mass gains, within the first year. Clitoral growth (termed clitoromegaly in clinical settings) typically begins within weeks and is well-established, though the degree varies considerably person to person, which the creator correctly flagged. The hunger surge is physiologically real: testosterone increases basal metabolic rate and lean muscle accretion, both of which drive caloric demand upward (Gooren, 2011, Best Practice and Research Clinical Endocrinology and Metabolism).

The jaw and dental shift claim is the most unusual one. There is emerging evidence that testosterone affects craniofacial bone remodeling, but large controlled studies in adult transmasculine populations are sparse. The creator should not be taken as a general predictor here.

What did they get wrong (or right)?

Mostly right, with one gap worth flagging. The blood draw interval they cite, every three to six months, is accurate for the monitoring phase but incomplete. The Endocrine Society's 2017 clinical practice guidelines specify that monitoring frequency depends on where you are in therapy: more frequent checks early on, with the possibility of extending to every six to twelve months once levels are stable. Saying "every three to six months" as a flat rule could give someone the impression that less frequent monitoring is always fine, which is not quite right.

The emotional changes section is honest and worth taking seriously. Research by Colizzi et al. (2014, Journal of Psychiatric Research) found reduced anxiety and improved psychological well-being in transmasculine individuals after initiating testosterone, but also noted some participants experienced new difficulty with emotional regulation, particularly anger. The creator's observation that they "deal with emotions completely different" aligns with what the literature documents, even if the mechanisms aren't fully understood yet.

What they got right: the individual variability disclaimer at the top is genuinely important and often skipped. The safety-first framing at the end is the correct message.

What should you actually know?

If you're considering or currently on testosterone therapy, the creator's experience is one data point, not a roadmap. Here is what the clinical picture actually looks like beyond this video.

• Hematocrit elevation is a real and under-discussed risk. Testosterone stimulates red blood cell production, and polycythemia can develop, which is why blood monitoring matters beyond just checking testosterone levels. Your provider should be checking a complete blood count, not just hormone levels (Fernandez et al., 2018, Andrology).
• Cardiovascular risk monitoring matters too, especially lipid panels. Testosterone tends to lower HDL cholesterol in transmasculine patients, a change that accumulates over years (Maraka et al., 2017, Annals of Internal Medicine).
• Bottom growth is permanent and begins early. Unlike many other changes, clitoral growth does not reverse if testosterone is discontinued.
• The hunger and metabolic shift is real, but muscle gain and fat redistribution are not guaranteed to look the same for everyone, and timelines vary significantly depending on starting body composition, dosing, and genetics.
• Voice changes can involve throat discomfort, as the creator described, but persistent hoarseness or pain that doesn't resolve warrants evaluation, not just patience.

The creator's parting shot, "you're not gonna be able to take hormone therapy if you're dead," is blunt and correct. Safety monitoring is not optional.